# Merck Ends Nemtabrutinib Development After Phase 3 Trial Review

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/59903
Published: 2026-11-17T22:13:06.000Z
Updated: 2026-11-17T22:13:06.000Z
Section: Business

> A data monitoring committee raised concerns that the drug’s potential benefits might not outweigh its risks.

During a Phase 3 trial review, a data monitoring committee raised concerns that nemtabrutinib’s potential benefits did not offset its risks; Merck & Co. has ended development of the drug.

Nemtabrutinib is an oral, non-covalent inhibitor of Bruton's tyrosine kinase (BTK).


